Loading
Pharvaris N.V. Stock: price and insider trades · United States
Pharvaris N.V.: what insiders have been doing
Pharvaris N.V., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). 28 insiders have disclosed 115 filings since 18 October 2025.
Only sales appear on the open market, 43 sales in all totalling €22.2M, filed by 10 insiders. One trade stands out by size: a sale of €6.1M from Schikan Johannes Gerardus Christiaan Petrus, disclosed on 21 September 2026, or 0.30% of market capitalisation.
The median gap between a trade and its publication by SEC (Form 4) is 2 days. The legal deadline for a Form 4 is two business days after the transaction. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives.
Across the 5,811 companies tracked on its exchange, the median is 19 filings; at 115 filings, this issuer sits above that mark. The full history, which starts in 2026, counts no purchases against 43 sales. For the fiscal year to 31 December 2025, the annual 20-F puts net income at -175.7 m EUR.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
115
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€22M
43 ops. · all time
Who traded when
BuySaleAnne Lesage12 sales
Johannes Gerardus Christiaan Petrus Schikan7 sales
Peng Lu7 sales
Berndt Modig6 sales
Abele Stefan Andreas3 sales
Robert Glassman3 sales
+4 other insiders
Analyst consensus: bullish or bearish?
Analysts rate Pharvaris N.V. Strong Buy (bullish), based on 14 analysts. Average price target: US$57.63.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$30.02
Analyst consensus
14 analystsStrong buy
US$41.07Target US$57.63(+92%)US$79.13
Income statement
EBITDA-US$169.4M
Net income-US$175.7M0.0% margin
Valuation
PER (forward)-11.0x
P/Book6.3x
Beta-2.46
Balance sheet & cash
Market capUS$2.1B
Total debtUS$776.8k
Free Cash Flow-US$137.2M
Debt / Equity0%
Profitability & ownership
ROE-70.5%
ROA-42.3%
% insiders6.1%
% institutions93.3%
Last declaration on 13 October 2026
Declarations115 total
11,969 shares@ US$33.04570.017% mcap80.4% of flowCommon StockSEC:0001193125-26-402567:1
11,969 shares@ US$8.050.0041% mcap19.6% of flowCommon StockSEC:0001193125-26-402567:0
800 shares@ US$20.000.0007% mcap0.2% of flowCommon StockSEC:0001193125-26-400435:0
800 shares@ US$36.190.0012% mcap0.4% of flowCommon StockSEC:0001193125-26-400435:1
11,969 shares@ US$33.04570.017% mcap100.0% of flowCommonSEC144:0001950047-26-009773
6,000 shares@ US$36.46680.0094% mcap100.0% of flowCommon StockSEC:0001193125-26-398678:0
500 shares0Common StockSEC:0001193125-26-398678:1
800 shares@ US$36.190.0012% mcap0.4% of flowCommonSEC144:0001950047-26-009744
6,000 shares@ US$36.46680.0094% mcap100.0% of flowCommonSEC144:0001950047-26-009695
14,493 shares@ US$18.140.011% mcap14.6% of flowCommon StockSEC:0001193125-26-396579:0
52,500 shares@ US$37.89350.085% mcap62.6% of flowCommon StockSEC:0001193125-26-396584:2
35,000 shares@ US$14.390.022% mcap15.8% of flowCommon StockSEC:0001193125-26-396584:0
300,000 shares@ US$35.000.45% mcap91.7% of flowCommon StockSEC:0001193125-26-396565:0
17,500 shares@ US$18.140.014% mcap10.0% of flowCommon StockSEC:0001193125-26-396584:1
14,493 shares@ US$38.55740.024% mcap31.1% of flowCommon StockSEC:0001193125-26-396579:1
20,000 shares@ US$38.27330.033% mcap18.2% of flowCommon StockSEC:0001193125-26-396572:0
200,000 shares@ US$35.000.30% mcap85.1% of flowCommon StockSEC:0001193125-26-396689:0
14,493 shares@ US$38.55740.024% mcap62.9% of flowCommonSEC144:0001950047-26-009612
300,000 shares@ US$35.000.45% mcap100.0% of flowCommonSEC144:0001950047-26-009653
52,500 shares@ US$37.89350.085% mcap100.0% of flowCommonSEC144:0001950047-26-009647
25 of 115 declarations
About Pharvaris N.V.
Pharvaris N.V. is a United States-listed biopharmaceutical company trading on the Nasdaq under the ticker PHVS, with operational headquarters in Zug, Switzerland and U.S.-market reporting obligations through the SEC. For investors, the company fits the profile of a late-stage specialty biotech focused on bradykinin-mediated diseases, especially hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH). Its core scientific thesis is built around novel oral bradykinin B2 receptor antagonists designed to address unmet needs in a disease area where convenience, speed of relief, and attack prevention remain central commercial and clinical issues. ([ir.pharvaris.com](https://ir.pharvaris.com/news-releases/news-release-details/pharvaris-reports-fourth-quarter-and-full-year-2025-financial?utm_source=openai))
Pharvaris was founded in the early 2020s and has since evolved into a clinical-stage company anchored by its lead asset, deucrictibant. The program includes both an immediate-release capsule and an extended-release tablet formulation. Positive phase 2 data in HAE supported advancement into pivotal development, with the company now evaluating deucrictibant in CHAPTER-3, a phase 3 study for the prevention of HAE attacks, and RAPIDe-3, a phase 3 study for on-demand treatment. In 2024, Pharvaris also expanded development plans into AAE-C1INH, broadening the potential commercial opportunity beyond classic hereditary disease. ([ir.pharvaris.com](https://ir.pharvaris.com/news-releases/news-release-details/pharvaris-reports-fourth-quarter-and-full-year-2024-financial?utm_source=openai))
Read moreShow less
From a competitive standpoint, Pharvaris is trying to differentiate itself in a relatively concentrated HAE market through an oral mechanism and patient-friendly dosing profile. That matters because existing HAE therapies often compete on efficacy but can be limited by route of administration, convenience, or dosing burden. Pharvaris therefore appears positioned as a focused challenger rather than a broad platform biotech: the upside case depends heavily on clinical efficacy, safety, regulatory progress, and eventual market adoption if approval is achieved. The company has also used capital raises to support development, underscoring the cash-intensive nature of late-stage biotech execution. ([ir.pharvaris.com](https://ir.pharvaris.com/news-releases/news-release-details/pharvaris-reports-fourth-quarter-and-full-year-2024-financial?utm_source=openai))
Geographically, Pharvaris is international in footprint: corporate presence in Switzerland, U.S. capital-markets access, and global clinical development activity. Recent highlights include full-year 2024 results, follow-on business updates in 2025 and 2026, and continued advancement of phase 3 studies. For market context, PHVS is therefore best viewed as a Nasdaq-listed United States company with an EU-based operational hub and a pipeline-driven equity story, highly sensitive to clinical readouts, regulatory milestones, and insider-transaction disclosures such as SEC Form 4 filings. ([ir.pharvaris.com](https://ir.pharvaris.com/news-releases/news-release-details/pharvaris-reports-fourth-quarter-and-full-year-2024-financial?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
